Drug-Nutrient Interactions in Patients Receiving Enteral Nutrition

Rollins, Carol J.

doi:10.1007/978-1-59259-781-9_26

Cited by 3 publications

(3 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dilution with 30–60 mL of water seems adequate for powdered medication 28 . ‐ 31 The volume required to dilute liquid medication depends on the desired degree of viscosity and/or osmolality. Diluting viscous suspensions in a volume of at least 1:1 seems to be adequate for some drugs 24 , 32 .…”

Section: Section 8 Medication Delivery Via Enteral Access Devicesmentioning

confidence: 99%

“…High‐osmolality medication can result in localized adverse effects at the mucosa or create an osmotic effect throughout portions of the bowel. The higher the osmolality, the greater the volume of diluent required to lower the osmolality 31 . The case has been made that it would be more practical to crush an acetaminophen tablet to a fine powder and disperse in a smaller volume of water than to use a liquid formulation that requires significant volume dilution 21 .…”

Section: Section 8 Medication Delivery Via Enteral Access Devicesmentioning

confidence: 99%

See 1 more Smart Citation

ASPEN Safe Practices for Enteral Nutrition Therapy

Boullata

Carrera²,

Harvey

et al. 2016

J Parenter Enteral Nutr

351

531

View full text Add to dashboard Cite

Enteral nutrition (EN) is a valuable clinical intervention for patients of all ages in a variety of care settings. Along with its many outcome benefits come the potential for adverse effects. These safety issues are the result of clinical complications and of process-related errors. The latter can occur at any step from patient assessment, prescribing, and order review, to product selection, labeling, and administration. To maximize the benefits of EN while minimizing adverse events requires that a systematic approach of care be in place. This includes open communication, standardization, and incorporation of best practices into the EN process. This document provides recommendations based on the available evidence and expert consensus for safe practices, across each step of the process, for all those involved in caring for patients receiving EN.

show abstract

Section: Section 8 Medication Delivery Via Enteral Access Devicesmentioning

confidence: 99%

Section: Section 8 Medication Delivery Via Enteral Access Devicesmentioning

confidence: 99%

ASPEN Safe Practices for Enteral Nutrition Therapy

Boullata

Carrera²,

Harvey

et al. 2016

J Parenter Enteral Nutr

351

531

View full text Add to dashboard Cite

show abstract

“…A recent review [169] discusses problems in extrapolating available data to current practice and provides recommendations for managing interactions of this type.…”

Section: Drug-food Interactionsmentioning

confidence: 99%